I had to deliver three talks; the first talk was on the role of the multidisciplinary tumour board in managing stage 3 disease of lung cancer. The main message is that the multidisciplinary tumour board gives a recommendation which are unique for this specific tumour board. They may differ between different institutions. The decision they do depends very much on the institutional experience but they are also based on guidelines, newer data which are integrated.
When it comes to stage 3 disease, there are two main questions to be answered. The first question – is stage 3 disease resectable or is it unresectable. In the first case, when it’s resectable, it’s treated by neoadjuvant treatment followed by surgery. If it’s unresectable it goes to a concept using chemoradiation plus immunotherapy.